NCT01283048View on ClinicalTrials.gov

Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Renal Cell Carcinoma
Interventions
DRUG

BKM-120 Bevacizumab

BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks

Trial Locations (3)

48201

Barbara Ann Karmanos Cancer Institute, Detroit

02215

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Beth Israel Deaconess Medical Center

OTHER

lead

Toni Choueiri, MD

OTHER

NCT01283048 - Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter